Core Insights - Cardlytics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.16, and an improvement from a loss of $0.15 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company generated revenues of $63.25 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.86% and down from $69.64 million year-over-year [2] - Cardlytics shares have declined approximately 50.4% year-to-date, contrasting with the S&P 500's gain of 7.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $70.3 million, and for the current fiscal year, it is -$0.46 on revenues of $275.2 million [7] - The estimate revisions trend for Cardlytics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Technology Services industry, to which Cardlytics belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]

Core Viewpoint - Green Thumb Industries Inc. reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.04, and showing a decline from earnings of $0.09 per share a year ago, indicating an earnings surprise of -125.00% [1] Financial Performance - The company posted revenues of $293.26 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.56%, and showing an increase from year-ago revenues of $280.15 million [2] - Over the last four quarters, Green Thumb Industries has not surpassed consensus EPS estimates, but has topped consensus revenue estimates three times [2] Stock Performance - Green Thumb Industries shares have declined approximately 11.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $285.85 million, and for the current fiscal year, it is $0.15 on revenues of $1.14 billion [7] Industry Outlook - The Medical - Products industry, to which Green Thumb Industries belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of the stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Protagonist Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.53, and compared to a loss of $0.50 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $5.55 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 46.67%, while year-ago revenues were $4.17 million [2] - Over the last four quarters, Protagonist Therapeutics has surpassed consensus EPS estimates three times, but the recent earnings surprise was -3.77% [1][2] Stock Movement and Outlook - Protagonist Therapeutics shares have increased by approximately 39.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates for the coming quarter at -$0.60 on revenues of $10.67 million, and for the current fiscal year at -$1.05 on revenues of $116.15 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Financial Performance - Soleno Therapeutics reported a quarterly loss of $0.09 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.53, and an improvement from a loss of $0.57 per share a year ago, representing an earnings surprise of +83.02% [1] - The company posted revenues of $32.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.58%, compared to zero revenues a year ago [2] Stock Performance - Soleno Therapeutics shares have increased approximately 81.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.49 on revenues of $24.62 million, and for the current fiscal year, it is -$2.13 on revenues of $122.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Soleno Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the company's stock may continue to perform well based on these revisions [5][6]

Core Insights - Intuitive Machines, Inc. (LUNR) is expected to report its second-quarter 2025 results on August 7, prior to market opening, with a history of outperforming earnings estimates in three of the last four quarters, averaging a 57.42% earnings surprise [1]. Group 1: Revenue and Earnings Performance - The second quarter is anticipated to show strong revenue growth driven by lunar payload, data analytics, and data transmission services for NASA and commercial contractors [2]. - Successful completion of the IM-2 mission is expected to contribute to revenue, with payments anticipated in the upcoming quarter, likely resulting in higher revenues reflected in the income statement [3]. - Despite strong revenue generation and higher gross profit from efficient program execution, increased selling, general, and administrative expenses due to investments in infrastructure and technology upgrades may negatively impact earnings [4]. Group 2: Financial Estimates - The Zacks Consensus Estimate for LUNR's second-quarter sales is projected at $68.4 million, representing a 65.2% increase from the same quarter last year [5]. - The consensus estimate for loss is set at six cents per share, indicating a decline from the previous year's loss of five cents [5]. Group 3: Earnings Prediction Model - The current model does not predict a definitive earnings beat for LUNR, with an Earnings ESP of -9.09% and a Zacks Rank of 4 (Sell), suggesting lower chances of outperforming earnings expectations [6][7].

Financial Performance - Nuveen Churchill Direct Lending Corp. reported quarterly earnings of $0.46 per share, matching the Zacks Consensus Estimate, but down from $0.57 per share a year ago [1] - The company posted revenues of $53.13 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.33% and down from $55.09 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2][3] Market Performance - Nuveen Churchill Direct Lending Corp. shares have declined approximately 5% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $54.9 million, and for the current fiscal year, it is $1.90 on revenues of $218.2 million [7] - The estimate revisions trend for the company was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Financial - SBIC & Commercial Industry, to which Nuveen Churchill Direct Lending Corp. belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Viewpoint - The report from Credit Lyonnais indicates that Lenovo Group is expected to achieve a profit of $480 million for the first fiscal quarter ending in June, which is 47% higher than the market expectation of $326 million [1] Financial Performance - The non-GAAP net profit, excluding the impact of convertible bonds and warrants, is projected to be $400 million, an 11% increase from previous forecasts [1] - The GAAP earnings estimates for fiscal year 2026 have been raised by 13% to $1.687 billion, while non-GAAP earnings estimates have been increased by 4% to $1.729 billion [1] - The GAAP earnings estimates for fiscal years 2027 and 2028 have also been adjusted upward by 9% [1] Business Segment Performance - The Intelligent Devices Group (IDG) revenue is expected to increase by 14% quarter-over-quarter, driven by demand in the U.S. market [1] Target Price and Rating - The target price for Lenovo has been raised from HKD 11 to HKD 12, with a reaffirmation of the "outperform" rating [1]

Company Performance - Masimo reported quarterly earnings of $1.33 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and up from $0.86 per share a year ago, representing an earnings surprise of +8.13% [1] - The company posted revenues of $370.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.59%, but down from $496.3 million year-over-year [2] - Over the last four quarters, Masimo has consistently surpassed consensus EPS estimates and revenue estimates [2] Future Outlook - The immediate price movement of Masimo's stock will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.14 on revenues of $369.36 million, and for the current fiscal year, it is $4.98 on revenues of $1.52 billion [7] - The estimate revisions trend for Masimo was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which Masimo belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance compared to higher-ranked industries [8] - The performance of Masimo's stock may also be influenced by the overall outlook for the industry [8]

Core Viewpoint - ONE Gas reported quarterly earnings of $0.53 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.48 per share a year ago [1] - The company posted revenues of $423.74 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.86% and up from $354.14 million year-over-year [2] Earnings Performance - The earnings surprise for the previous quarter was +7.03%, with actual earnings of $1.98 per share compared to an expected $1.85 [1] - Over the last four quarters, ONE Gas has surpassed consensus EPS estimates two times [1] Revenue Performance - The company has also topped consensus revenue estimates two times over the last four quarters [2] Stock Performance - ONE Gas shares have increased by approximately 5.9% since the beginning of the year, while the S&P 500 has gained 7.6% [3] Future Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.54 on revenues of $383.09 million, and for the current fiscal year, it is $4.29 on revenues of $2.43 billion [7] Industry Context - The Utility - Gas Distribution industry is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]

Jushi Holdings Inc. (JUSHF) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.09, delivering a surprise of -50%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Jushi Holdings Inc. shares ha ...